Healthtech Solutions, Inc. (HLTT), Parent Company of Cutting-Edge Medical Technology Companies, Files Reg A With SEC
17 mars 2021 08h30 HE
|
Healthtech Solutions, Inc.
March 8, 2021, filing to raise up to $75 million. Maximum of 1,500,000 shares of Series B preferred stock offered at price of $50 per share.Healthtech Solutions, Inc. is organized to pursue...
Healthtech Solutions, Inc. (HLTT), Parent Company of Medi-Scan Inc., Announces Incorporation of a New Subsidiary Called RevHeart, Inc.
16 mars 2021 08h30 HE
|
Healthtech Solutions, Inc.
New subsidiary will further the Company’s research into treating COVID-related heart muscle injury. A patent has been filed for a therapy to ameliorate and potentially repair myocardial damage. NEW...
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
19 janv. 2021 08h05 HE
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
Integer’s Alden, N.Y. Location Breaks Ground on Building Expansion
14 janv. 2021 16h05 HE
|
Integer Holdings Corporation
~ Expansion to Significantly Increase Plant’s Production Capacity of Xcellion® Lithium Ion Rechargeable Batteries ~ PLANO, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integer Holdings Corporation...
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
13 nov. 2020 10h00 HE
|
InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
21 oct. 2020 08h05 HE
|
InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
CB Scientific, Inc. (CBSC) Announces the Launch of My-Cardia ECG Products and Services in Thailand
08 oct. 2020 08h00 HE
|
CB Scientific, Inc.
ESCONDIDO, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- via Network Wire -- CB Scientific. Inc. (OTC:CBSC) ("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory...
CB Scientific, Inc. (CBSC) Announces Completion of Asset Purchase Agreement and Commencement of Its ECG Monitoring Business
22 sept. 2020 08h00 HE
|
CB Scientific, Inc.
ESCONDIDO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CB Scientific, Inc. (OTC: CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory...
Electrosurgical Generators Market revenue to hit USD 2.5 Bn by 2025: Global Market Insights, Inc.
22 déc. 2019 19h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Dec. 22, 2019 (GLOBE NEWSWIRE) -- According to latest report “Electrosurgical Generators Market by Type (Bipolar, Monopolar), Application (Optical, Gynecology, Dermatology,...
CITIZEN CPR FOUNDATION ISSUES A CALL TO ACTION TO SAVE LIVES FROM SUDDEN CARDIAC ARREST
13 déc. 2019 12h07 HE
|
Citizen CPR Foundation
Seattle, Washington, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Wrapping up four days of cutting-edge education and motivation to help reinforce the strength of the “chain of survival,” the Citizen CPR...